CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
← catalyst calendarNCT06834282 · readout in 134 d
Sponsored by CERo Therapeutics Holdings, Inc. (industry) · CERO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
18estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- AML
- Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- Drug: CER-1236
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Mesna
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs) and serious adverse events (SAEs) - (Part 1)
measured 2 year
Incidence of dose-limiting toxicities (DLTs) of CER-1236 Monotherapy - (Part 1)
measured 28 days
Estimation of the objective response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD) negativity rates - (Part 2)
measured 2 years
Permalink · CERO's whole pipeline · Catalyst calendar · Every registered study · What changed